PET/MRI to Stage Prostate Cancer Patients

Launched by IRCCS SAN RAFFAELE · Jun 25, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to better stage prostate cancer using a special type of imaging called PET/MRI. This method combines two advanced imaging techniques to get a clearer picture of the cancer in the body by using specific substances that highlight the cancer cells. The trial will involve 50 men who have been diagnosed with high-grade prostate cancer and are planning to have surgery to remove the prostate and nearby lymph nodes.

To participate in this study, men must be at least 18 years old and have a confirmed diagnosis of high-grade prostate cancer. They should also be willing to sign a consent form to participate. Unfortunately, those who have conditions that make it hard to complete the imaging or have certain medical devices, like pacemakers, will not be eligible. Participants can expect to undergo the PET/MRI imaging before their surgery, which will help doctors gather important information about the cancer. This trial aims to improve how doctors understand and treat prostate cancer, ultimately leading to better care for patients.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years-old
• • Biopsy proven high-grade PCa referred to prostatectomy and pelvic/retroperitoneal lymphadenectomy.
• • Willing to provide a signed informed consent
• Exclusion Criteria:
• • Age \< 18 years-old
• • Inability to complete the needed imaging examinations (i.e. severe claustrophobia)
• • Any additional medical condition that may significantly interfere with study compliance
• • All the contraindications for MRI study (i.e. pacemaker)
• • Evidence of metastatic disease on conventional imaging contraindicating the surgical procedure